Analyst Observations
Published: May 20, 2025
This content is for informational purposes only. This should not be construed as solicitation. The general public should consult their financial advisor for additional information related to investment decisions.
Comments include: CAH, LLY, OKLO, & TSLA.

 

CAH Cardinal Health, Inc. ($154.73) - Drugs - CAH moved higher to break a double top at $156, marking its third consecutive buy signal and a new all-time high. The 5 for 5’er has been in a positive trend since 2023 and ranks third out of 42 in the drugs sector matrix. The Weekly OBOS indicates that the stock is in heavily overbought territory, so wait for the 10-week trading band to normalize before considering. Initial support is at $144 with additional support at $130.
LLY Eli Lilly and Company ($743.88) - Drugs - LLY shares moved higher today to break a double top at $760 to mark its first buy signal. This 2 for 5'er has been in a negative trend since May but on an RS buy signal versus the market since August 2021. LLY shares are trading below the middle of their ten-week trading band with a weekly overbought/oversold reading of -27%. From here, support is offered at $720.
OKLO Oklo Inc. ($37.36) - Utilities/Electricity - OKLO broke a triple top at $40 for a second buy signal as shares rallied to $41. This move also shifts the trend back to positive, which along with the notable market RS chart changes in recent weeks, will increase the stock to a 4 for 5'er. Okay to consider the stock in the upper $30 range. Initial support lies at $35, while prior resistance at $31 may be seen as an additional level of near-term support.
TSLA Tesla Inc. ($342.21) - Autos and Parts - TSLA broke a triple top at $352 for a third consecutive buy signal. TSLA is a 5 for 5'er that ranks 5th (out of 47) within the Autos and Parts sector matrix. This action places the stock in overbought territory, so those seeking expsoure may look to dollar cost average into a position or consolidation within the $340 to $350 range. Initial support now resides at $336.
Back to report

DISCLOSURE

This report is for Internal Use Only and not for distribution to the public. While we make every effort to be free of errors in this report, it contains data obtained from other sources. We believe these sources to be reliable, but we cannot guarantee their accuracy. Investors who use options should read the Options Disclosure Document before making any particular investment decision. Officers or employees of this firm may now or in the future have a position in the stocks mentioned in this report. Dorsey, Wright is a Registered Investment Advisor with the U.S. Securities & Exchange Commission. Copies of Form ADV Part II are available upon request.
Equity prices provided by Thomson-Reuters. Cross Rate prices provided by Tenfore Systems. Option prices provided by OPRA
Copyright © 1995-{ENDYEAR} Dorsey, Wright & Associates, LLC.®
All quotes displayed are delayed 20 minutes
Disclaimer/Terms of Use/Copyright